X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RPT193 (zelnecirnon) is an antagonist of CCR4 receptor that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17. It is being evaluated for the treatment of atopic dermatitis.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
RPT193 is a small molecule, CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues In allergic inflammatory diseases such as atopic dermatitis and asthma.
Lead Product(s): Zelnecirnon
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
RPT193 is an orally-administered small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in a broad range of inflammatory disorders.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2022
Details:
In a post-hoc statistical analysis comparing RPT193-treated patients to placebo-treated patients, the improvements in EASI, EASI-50 and BSA at Day 43 were statistically significant. RPT193 was well tolerated in the Phase 1b study.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The biomarker data, showed patients treated with RPT193 experienced a statistically significant improvement (p<0.001) in the meta-analysis derived atopic dermatitis (MADAD) score, a well-established gene signature that tracks with disease severity.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
RPT193 is a small molecule CCR4 antagonist that blocks the recruitment of inflammatory immune cells, known as Th2 cells, which are clinically implicated in allergic inflammatory disorders, such as atopic dermatitis.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
In the Phase 1b study, 21 patients with moderate-to-severe atopic dermatitis were treated with 400 mg of RPT193, administered orally once a day for four weeks, while 10 patients received placebo.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
RAPT’s Phase 1b study is part of a first-in-human Phase 1a/1b trial of RPT193. The Phase 1b portion of the trial is a randomized, double-blind, placebo-controlled study in patients with moderate to severe AD.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: RPT193
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
In multiple preclinical studies of allergic skin inflammation, once-daily dosing of RPT193 demonstrated efficacy and reduction of Th2 cytokines comparable to treatment with currently available biologics that work by blocking interleukin-4 (IL-4) and IL-13.
Lead Product(s): Zelnecirnon
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
